.

follow-on-google-news

The year 2022 has not been very favorable for the Big Bull of India and most of the Rakesh Jhunjhunwala Portfolio stocks are severely hit this year. Apart from a few stocks that gave positive returns like Indian Hotels Company, CRISIL, Metro Brands and DB Realty, the rest majority of the companies in his portfolio are in the ‘Red’ this year.

Here are two of the worst performing companies in Rakesh Jhunjhunwala Portfolio that are currently trading near their 52-week lows:

Rallis India Limited

Rallis India is a Tata Group stock that is involved in the manufacturing of Agrochemicals and offers a robust product portfolio offering comprehensive crop care solutions, including formulations for crop protection and nutrition.

Note: If you want to learn Candlesticks and Chart Trading from Scratch, here’s the best book available on Amazon! Get the book now!

The shares of Rallis India Limited are currently trading at their 52-week lows with a share price of Rs 3,697.82 apiece. The stocks have given a negative return of -31.33% this year YTD and declined -47.56% from their 52-week highs. Rakesh Jhunjhuwala is currently holding over 1.9 crore shares of the company with a holding value of Rs 363.8 Cr as per Mar’22 reports.

Jubilant Pharmova Ltd

Jubilant Pharmova Ltd is a global pharmaceuticals company having three business segments that is Pharmaceuticals, Contract Research and Development Services, and Proprietary Novel Drugs.

Jubilant Pharmova Ltd shares are currently trading its 52-week low at the share price of Rs 357.30 a piece. The stocks have declined by -39.46% in 2022. Rakesh Jhunjhuwala is currently holding over 1.07 crore shares of the company with a holding value of Rs 388 Cr as per Mar’22 reports.

Disclaimer

The content in this news article is not investment advice. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.